Functional measurement of mitogen-activated protein kinase pathway activation predicts responsiveness of RAS-mutant cancers to MEK inhibitors

Press Release Mar 11 2021 Fore Biotherapeutics Enters Pharma Business With BRAF Inhibitor as Lead Product Read more

Press Release Sep 21 2020 Novellus Closes $57M Series C Financing Read more

Press Release Jun 03 2020 Novellus Executes Exclusive Worldwide License Agreement with Plexxikon for PLX8394, Plexxikon’s Next-Generation, Clinical StageBRAF Inhibitor Read more